MARKET

CPRX

CPRX

Catalyst Pharmaceuticals Inc
NASDAQ
16.49
+0.09
+0.55%
After Hours: 16.35 -0.14 -0.85% 19:58 05/17 EDT
OPEN
16.55
PREV CLOSE
16.40
HIGH
16.85
LOW
16.32
VOLUME
1.11M
TURNOVER
0
52 WEEK HIGH
17.50
52 WEEK LOW
11.09
MARKET CAP
1.95B
P/E (TTM)
30.63
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at CPRX last week (0506-0510)?
Weekly Report · 6d ago
Bank of America Securities Sticks to Their Buy Rating for Catalyst Pharma (CPRX)
TipRanks · 05/10 15:16
Decoding 8 Analyst Evaluations For Catalyst Pharmaceuticals
Eight analysts have published ratings on Catalyst Pharmaceuticals (NASDAQ:CPRX) in the last three months. The company has an average 12-month price target of $28.88, with a high estimate of $34.00. The biopharmaceutical company focuses on developing therapies for rare diseases.
Benzinga · 05/10 14:00
Catalyst Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 05/10 12:22
Catalyst Pharmaceuticals Price Target Raised to $26.00/Share From $24.00 by HC Wainwright & Co.
Dow Jones · 05/10 12:22
HC Wainwright & Co. Maintains Buy on Catalyst Pharmaceuticals, Raises Price Target to $26
Benzinga · 05/10 12:11
Truist Financial Keeps Their Buy Rating on Catalyst Pharma (CPRX)
TipRanks · 05/10 12:09
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Catalyst Pharma (CPRX), Xenon (XENE) and Intellia Therapeutics (NTLA)
TipRanks · 05/10 11:10
More
About CPRX
Catalyst Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on developing and commercializing first-in-class medicines that address rare and difficult to treat diseases. Its flagship commercial product is FIRDAPSE (amifampridine) tablets 10 milligrams (mg), approved for the treatment of Lambert-Eaton Myasthenic Syndrome (LEMS) for adults and for children ages six to seventeen. The Company is also marketing FYCOMPA (perampanel) CIII as a prescription medication used alone or with other medicines to treat focal onset seizures with or without secondarily generalized seizures in people with epilepsy aged four and older and with other medicines to treat primary generalized tonic-clonic seizures in people with epilepsy aged 12 and older. Its portfolio also includes AGAMREE (vamorolone) an oral suspension 40 mg/ml for the treatment of Duchenne Muscular Dystrophy (DMD). The vamorolone is a corticosteroid treatment for patients suffering from DMD.

Webull offers Catalyst Pharmaceuticals Inc stock information, including NASDAQ: CPRX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CPRX stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CPRX stock methods without spending real money on the virtual paper trading platform.